US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

41.48

+1.814.56%

Pre-market: 41.21-0.2707-0.65%09:27 EDT

Volume:254.55K

Turnover:10.50M

Market Cap:259.25M

PE:- -

High:41.49

Open:40.08

Low:40.08

Close:39.67

52wk High:41.49

52wk Low:22.12

Shares:6.25M

Float Shares:6.25M

Volume Ratio:2.18

T/O Rate:4.07%

Dividend:0.28

Dividend Rate:0.68%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vertex Pharmaceuticals (VRTX) Receives a Buy from BMO Capital

Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform

Cogstate lifts profit and doubles dividend as clinical trials revenue surges

Vortex Energy Appoints Market Maker to Boost Liquidity on CSE

Vertex (VERX) Is Up 6.5% After Q2 Profit, Raised 2026 Outlook And New AI-Focused Hires

Simply Wall St.

Incyte : Piper Sandler Raises Target Price to $130 from $110

THOMSON REUTERS

Moderna (MRNA) Starts Ebola Vaccine Trial As Fair Value Questions Persist

Simply Wall St.

Twist Bioscience CEO Emily Leproust Disposes of Common Shares Worth $2.5 Million

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,803 Shares for $1.3 Million

Crinetics nears shareholder vote on Vertex merger

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults

PDS Biotech Reports Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IDNA/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":41.48,"timestamp":1787688000000,"preClose":39.67,"halted":0,"volume":254554,"hourTrading":{"tag":"盘前","latestPrice":41.2093,"preClose":41.48,"latestTime":"09:27 EDT","volume":16,"amount":665.699408,"timestamp":1787750854149,"change":-0.2707,"changeRate":-0.006526,"amplitude":0.04317},"delay":0,"changeRate":0.045626417948071464,"floatShares":6250000,"shares":6250000,"eps":0,"marketStatus":"Pre-Mkt","change":1.81,"latestTime":"08-26 09:28:49 EDT","open":40.08,"high":41.49,"low":40.08,"amount":10495342.87728,"amplitude":0.035543,"askPrice":42.42,"askSize":100,"bidPrice":39.79,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787751000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":41.48,"sharesOutstanding":5100000,"nav":39.56427,"aum":247276687.5,"dividendRate":0.006791,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":41.2093,"preClose":41.48,"latestTime":"09:27 EDT","volume":16,"amount":665.699408,"timestamp":1787750854149,"change":-0.2707,"changeRate":-0.006526,"amplitude":0.04317},"postHourTrading":{"tag":"盘后","latestPrice":41.48,"preClose":41.48,"latestTime":"19:38 EDT","volume":175,"amount":7299.68,"timestamp":1787701127157,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.180001846103913,"impliedVol":0.091,"impliedVolPercentile":0.132},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.180001846103913,"shares":6250000,"dividePrice":0.2817,"high":41.49,"amplitude":0.035543,"preClose":39.67,"low":40.08,"week52Low":22.12,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":41.48,"eps":0,"divideRate":0.006791,"volume":254554,"delay":0,"ttmEps":0,"open":40.08,"prevYearClose":26.19,"fiveDayClose":35.98,"twentyDayClose":32.4473,"sixtyDayClose":29.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660464901","title":"Vertex Pharmaceuticals (VRTX) Receives a Buy from BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660464901?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:37","pubTimestamp":1787053066,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $600.00. The company’s sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vertex-pharmaceuticals-vrtx-receives-a-buy-from-bmo-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vertex-pharmaceuticals-vrtx-receives-a-buy-from-bmo-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2468319806.SGD","IBB","LU1093756325.SGD","LU1559883803.SGD","SG9999001176.SGD","BK4207","TBXU","IE00B19Z9P08.USD","LU1674673428.USD","SGXZ57979304.SGD","LU2362540622.SGD","BK4023","VERX","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD","BMO","BIB","LU2089984988.USD","IE0009355771.USD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU0566484027.USD","IE00B19Z3B42.SGD","BBH","LU0417517546.SGD","SG9999013999.USD","PBE","VRTX","BK4585","GNMX","LU0058720904.USD","IBBQ","LU0061475181.USD","LU0079474960.USD","LU2324357040.USD","LU0823416689.USD","SG9999001176.USD","BK4567","LU1674673691.USD","IDNA","LU2236285917.USD","LU1035775433.USD","LU0109394709.USD","IE00B19Z3581.USD","LU2417539215.USD","LU1069344957.HKD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443063","title":"Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443063","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443063?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:49","pubTimestamp":1787006950,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has shared an update. Cogstate Ltd is a science-led clinical trial endpoint specialist focused on central nervous system...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHAT","CNS","NVIB","MEDX","HYLG","GDOC","IDNA","BK4135","AIPO","VTHR","AGIX","QTOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660306364","title":"Cogstate lifts profit and doubles dividend as clinical trials revenue surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2660306364","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660306364?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:48","pubTimestamp":1787006906,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has provided an announcement. Cogstate Ltd, a provider of digital cognitive assessment solutions for global clinical tri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIG","NVIB","GDOC","BMED","MEDX","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431812","title":"Vortex Energy Appoints Market Maker to Boost Liquidity on CSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431812?lang=en_us&edition=fundamental","pubTime":"2026-08-18 01:07","pubTimestamp":1786986428,"startTime":"0","endTime":"0","summary":"An announcement from Vortex Energy Corp. ( ($TSE:VRTX) ) is now available. Vortex Energy Corp., a North American mineral exploration company, is ad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vortex-energy-appoints-market-maker-to-boost-liquidity-on-cse?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vortex-energy-appoints-market-maker-to-boost-liquidity-on-cse?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9P08.USD","LU0256863811.USD","IDNA","LU0058720904.USD","LU1069344957.HKD","LU1093756168.USD","IE0002141913.USD","BK4588","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","SG9999001176.USD","LU2362541273.HKD","VRTX","LU0109394709.USD","LU2468319806.SGD","BK4139","IE00B19Z3581.USD","LU2089984988.USD","PBE","LU0889565916.HKD","LU2362541513.USD","TBXU","LU0417517546.SGD","LU2362540622.SGD","IBB","LU0320765992.SGD","LU1778281490.HKD","LU2417539215.USD","LU0079474960.USD","BK4533","SG9999013999.USD","IBBQ","BK4585","LU1430594728.SGD","LU2236285917.USD","IE0009355771.USD","LU0234570918.USD","LU2237438978.USD","GNMX","BIB","BBH","IE0002270589.USD","LU0823416689.USD","BK4567","LU2324357040.USD","LU0289739699.SGD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660102443","title":"Vertex (VERX) Is Up 6.5% After Q2 Profit, Raised 2026 Outlook And New AI-Focused Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2660102443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660102443?lang=en_us&edition=fundamental","pubTime":"2026-08-17 12:42","pubTimestamp":1786941762,"startTime":"0","endTime":"0","summary":"In early August 2026, Vertex, Inc. reported second-quarter revenue of US$203.97 million, returning to quarterly profitability, issued updated 2026 guidance, and announced three senior leadership appointments across people, Europe, and product and technology.\nThe combination of stronger quarterly results, clearer near-term revenue expectations, and experienced hires to drive SaaS and AI innovation signals management’s focus on scaling execution and international expansion.\nNext, we’ll examine...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-is-up-65-after-q2-profit-raised-2026-outlook-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-is-up-65-after-q2-profit-raised-2026-outlook-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1674673691.USD","LU1778281490.HKD","LU1093756168.USD","IE00B19Z3581.USD","LU1035775433.USD","LU0061475181.USD","LU1585245621.USD","CHAT","LU2237438978.USD","LU1674673428.USD","LU2324357040.USD","LU2362541513.USD","VERX","IDNA","AGIX","LU2362541273.HKD","IE00BJJMRZ35.SGD","QTOC","LU2468319806.SGD","IE0002270589.USD","VRTX","SG9999013999.USD","LU0256863811.USD","LU1093756325.SGD","ARTY","IBBQ","LU1559883803.SGD","LU2462157665.USD","LU0234570918.USD","IE00B2B36J28.USD","TBXU","SG9999001176.SGD","PBE","IE00BJT1NW94.SGD","IE00B894F039.SGD","IBB","LU2362540622.SGD","GNMX","LU0058720904.USD","LU2456880835.USD","BK4567","AIPO","BBH","LU0823416689.USD","VTHR","LU0432979614.USD","LU0079474960.USD","BIB","LU0109394709.USD","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660041981","title":"Incyte : Piper Sandler Raises Target Price to $130 from $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660041981?lang=en_us&edition=fundamental","pubTime":"2026-08-17 12:33","pubTimestamp":1786941228,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44C022:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","BK4585","IDNA","BK4139","BK4532","BK4588","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179630","title":"Moderna (MRNA) Starts Ebola Vaccine Trial As Fair Value Questions Persist","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179630","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659179630?lang=en_us&edition=fundamental","pubTime":"2026-08-16 05:20","pubTimestamp":1786828815,"startTime":"0","endTime":"0","summary":"Health Canada has cleared Moderna (MRNA) to begin a Phase I clinical trial of its mRNA Ebola vaccine targeting the Bundibugyo virus, giving investors another data point on the company’s expanding infectious disease pipeline.\nSee our latest analysis for Moderna.\nModerna’s US$63.32 share price has been volatile, with a 7.01% 7 day share price gain and a 29.12% 90 day share price return. The 125.98% 1 year total shareholder return contrasts with a weaker 3 and 5 year record. Recent regulatory...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-mrna-starts-ebola-vaccine-trial-as-fair-value-questi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-mrna-starts-ebola-vaccine-trial-as-fair-value-questi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4533","BK4548","MRNA","MRNX","IDNA","LGHT","GNOM","WDNA","BK4501","MRNY","BK4534","BK4139","BK4551","BK4568","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126777","title":"Twist Bioscience CEO Emily Leproust Disposes of Common Shares Worth $2.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126777","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126777?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:09","pubTimestamp":1786738148,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO Emily Leproust disposes of common shares worth $2.5 millionTwist Bioscience CEO Emily M. Leproust exercised stock options for 19,952 shares on Aug. 12, 2026 at USD 26.66.She sold ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2Cx15Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Twist Bioscience CEO Emily Leproust Disposes of Common Shares Worth $2.5 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GNOM","BK4139","IDNA","BK4588","TWST","ARKG","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126775","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126775?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":"EB-003 Development Highlights:--  Continued advancing IND-enabling studies supporting the planned. submission of an Investigational New Drug  application for EB-003. --  Reported preclinical data demonstrating that EB-003 consistently. exhibited a non-hallucinogenic profile in a highly sensitive. --  Announced promising results from preclinical in vitro experiments. indicating no photoreactive potential for EB-003, further derisking its. continued development as a potential treatment of neuropsychiatric. --  Initiated genotoxicity studies to evaluate the potential for EB-003 to. interact with DNA and cause genetic mutations, a critical measure of. --  Secured U.S. Patent No. 12,605,361 pertaining to the Company's EVM301. Series of molecules being developed as potential treatments for mental","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","GDOC","ENVB","IDNA","BK4604","BK4555","IND","TM","BK4007","NVIB","MEDX","HYLG","BK4099","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659262381","title":"Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,803 Shares for $1.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659262381","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659262381?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:03","pubTimestamp":1786737791,"startTime":"0","endTime":"0","summary":"Incyte President, Global Head of R&D Pablo J. Cagnoni sells 10,803 shares for $1.3 millionPablo J. Cagnoni, President, Global Head of R&D at Incyte, sold 10,803 common shares on Aug. 12.Shares were so","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1QzvFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,803 Shares for $1.3 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","BK4550","BK4588","BK4585","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144409","title":"Crinetics nears shareholder vote on Vertex merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144409","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144409?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:21","pubTimestamp":1786713691,"startTime":"0","endTime":"0","summary":"An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July 6, 2026, Crinetics Pharmaceuticals agreed to merge with Vertex Pharm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crinetics-nears-shareholder-vote-on-vertex-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crinetics-nears-shareholder-vote-on-vertex-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.USD","LU1093756168.USD","LU0256863811.USD","LU2362541513.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","MRGR","LU1674673691.USD","LU2237438978.USD","LU1674673428.USD","BIB","LU0566484027.USD","TBXU","VRTX","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","SG9999013999.USD","IE00BZ9MQY76.HKD","IE00BJJMRZ35.SGD","IBB","BBH","VERX","IDNA","RSBA","LU0889565916.HKD","LU1778281490.HKD","LU0109394709.USD","LU0058720904.USD","BK4139","LU0079474960.USD","SG9999001176.SGD","BK4588","LU1069344957.HKD","LU2362541273.HKD","GNMX","IE00B894F039.SGD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU1815336091.USD","LU2089984988.USD","IE00B19Z9P08.USD","IBBQ","IE0009355771.USD","LU2324357040.USD","PBE","LU2362540622.SGD","LU2462157665.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4503","PLTM","BK4539","GDOC","BK4551","ALLR","BK4535","BK4023","BMED","BK4007","IDNA","CDMO","CLIA","NVIB","BK4139","API"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","IDNA","CAR","MEDX","SLE","BK4230","NVIB","GDOC","BMED","BK4077","BK4139","LABU","HYLG","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","BK4097","BK4139","MSLE","GDOC","IND","MEDX","PRGS","NVIB","HYLG","IDNA","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659627661","title":"CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659627661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659627661?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344920/0/en/camp4-reports-second-quarter-2026-financial-results-and-corporate-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","NVIB","GDOC","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4568","BK4022","GDOC","BK4551","BK4535","BK4232","BNTX","BK4548","HYLG","BK4139","IND","MEDX","IVVD","IDNA","NVIB","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LFSC","CAR","TBXU","SYNB","PFS","CR","BK4230","BK4161","HYLG","LD","NVIB","BK4022","BK4585","BK4139","IDNA","GNOM","GDOC","MEDX","ORR","CRBU","IBB","BK4588","FBT","CNCR","BK4539","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162812","title":"Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162812","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162812?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344883/0/en/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","IDNA","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166082","title":"Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166082","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166082?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:30","pubTimestamp":1786638638,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new early-stage trial called “A Phase 1, Random...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moderna-expands-respiratory-vaccine-pipeline-with-new-rsv-hmpv-trial-in-older-adults?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moderna-expands-respiratory-vaccine-pipeline-with-new-rsv-hmpv-trial-in-older-adults?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4532","BK4548","BK4139","BK4588","BK4501","BK4568","MRNA","MRNX","MRNY","WDNA","BK4585","BK4551","BK4533","IDNA","LGHT","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","XBI","GDOC","PDS","BK4092","HYLG","NVIB","BK4581","BK4585","MEDX","BK4211","IDNA","ORR","BK4195","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":12,"totalSize":248,"code":"91000000","status":"200"}]}}